Cargando…
The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic
A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course afte...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470206/ https://www.ncbi.nlm.nih.gov/pubmed/34572585 http://dx.doi.org/10.3390/biom11091372 |
_version_ | 1784574139340685312 |
---|---|
author | Azimzadeh, Maryam Möhn, Nora Ghane Ezabadi, Sajjad Moghimi Esfandabadi, Zahra Soleimani, Alireza Ranjbar, Elaheh Jahromi, Maliheh Seyedebrahimi, Reihaneh Skripuletz, Thomas Moharrami Kasmaie, Farshad |
author_facet | Azimzadeh, Maryam Möhn, Nora Ghane Ezabadi, Sajjad Moghimi Esfandabadi, Zahra Soleimani, Alireza Ranjbar, Elaheh Jahromi, Maliheh Seyedebrahimi, Reihaneh Skripuletz, Thomas Moharrami Kasmaie, Farshad |
author_sort | Azimzadeh, Maryam |
collection | PubMed |
description | A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-8470206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84702062021-09-27 The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic Azimzadeh, Maryam Möhn, Nora Ghane Ezabadi, Sajjad Moghimi Esfandabadi, Zahra Soleimani, Alireza Ranjbar, Elaheh Jahromi, Maliheh Seyedebrahimi, Reihaneh Skripuletz, Thomas Moharrami Kasmaie, Farshad Biomolecules Review A growing body of evidence initially suggested that patients with multiple sclerosis (MS) might be more susceptible to coronavirus disease 2019 (COVID-19). Moreover, it was speculated that patients with MS treated with immunosuppressive drugs might be at risk to develop a severe diseases course after infection with the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV2). However, the recently published data have shown that MS patients do not have a higher risk for severe COVID-19. Although there is no indication that patients with MS and immunomodulatory/immunosuppressive therapy are generally at a higher risk of severe COVID-19, it is currently being emphasized that the hazards of poorly treated MS may outweigh the putative COVID-19 dangers. In this review, we discuss the challenges and considerations for MS patients in the COVID-19 pandemic. MDPI 2021-09-17 /pmc/articles/PMC8470206/ /pubmed/34572585 http://dx.doi.org/10.3390/biom11091372 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Azimzadeh, Maryam Möhn, Nora Ghane Ezabadi, Sajjad Moghimi Esfandabadi, Zahra Soleimani, Alireza Ranjbar, Elaheh Jahromi, Maliheh Seyedebrahimi, Reihaneh Skripuletz, Thomas Moharrami Kasmaie, Farshad The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic |
title | The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic |
title_full | The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic |
title_fullStr | The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic |
title_full_unstemmed | The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic |
title_short | The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic |
title_sort | immunological therapeutic strategies for controlling multiple sclerosis: considerations during the covid-19 pandemic |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470206/ https://www.ncbi.nlm.nih.gov/pubmed/34572585 http://dx.doi.org/10.3390/biom11091372 |
work_keys_str_mv | AT azimzadehmaryam theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT mohnnora theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT ghaneezabadisajjad theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT moghimiesfandabadizahra theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT soleimanialireza theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT ranjbarelaheh theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT jahromimaliheh theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT seyedebrahimireihaneh theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT skripuletzthomas theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT moharramikasmaiefarshad theimmunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT azimzadehmaryam immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT mohnnora immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT ghaneezabadisajjad immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT moghimiesfandabadizahra immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT soleimanialireza immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT ranjbarelaheh immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT jahromimaliheh immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT seyedebrahimireihaneh immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT skripuletzthomas immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic AT moharramikasmaiefarshad immunologicaltherapeuticstrategiesforcontrollingmultiplesclerosisconsiderationsduringthecovid19pandemic |